Recent Quotes
My Watchlist
Indicators
Markets
Stocks
Funds
Tools
Overview
News
Currencies
International
Treasuries

Myovant Sciences Ltd (NY: MYOV )

22.46 USD +0.71 (+3.26%)
Official Closing Price Updated: 7:53 PM EST, Feb 26, 2021 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

Price and Volume

Detailed Quote
Volume 496,800
Open 21.99
Bid (Size) 21.80 (5)
Ask (Size) 22.66 (4)
Prev. Close 21.75
Today's Range 21.38 - 22.62
52wk Range 5.980 - 30.90
Shares Outstanding 14,500,000
Dividend Yield N/A
Chart for (: )
Intraday 1 Week 1 Month 3 Month 1 Year

Top News

More News
Myovant Sciences to Present at Upcoming Investor Conferences
From GlobeNewswire News Releases
Sumitovant Biopharma Announces Publication in the New England Journal of Medicine of Myovant Sciences Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
•LIBERTY 1 and LIBERTY 2 achieved 73.4% and 71.2% response rates in menstrual blood loss, with an average reduction of 84.3% from baseline •Achieved six of seven key secondary endpoints including... 
From GlobeNewswire News Releases

Performance

YTD
-9.54%
-9.54%
1 Month
-1.84%
-1.84%
3 Month
-4.55%
-4.55%
6 Month
+13.15%
+13.15%
1 Year
+133.71%
+133.71%

More News

Read More
Myovant Sciences and Pfizer Announce Publication in the New England Journal of Medicine of Phase 3 LIBERTY Studies of Once-Daily Relugolix Combination Therapy in Women with Uterine Fibroids
From GlobeNewswire News Releases
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
From GlobeNewswire News Releases
HealthyWomen and Myovant Sciences Launch “Voices of Periods” to Fight Menstrual Stigma
From GlobeNewswire News Releases
Myovant Sciences Announces Corporate Updates and Financial Results for Third Quarter of Fiscal Year 2020
From GlobeNewswire News Releases
Myovant Sciences to Host Third Fiscal Quarter 2020 Earnings Conference Call at 8:30 a.m. Eastern Time on February 11, 2021
From GlobeNewswire News Releases
UPDATE: Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
From GlobeNewswire News Releases
Sumitovant Biopharma Announces Myovant Sciences Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
From GlobeNewswire News Releases
Myovant Sciences and Pfizer Announce Positive One-Year Data from Phase 3 SPIRIT Extension Study of Once-Daily Relugolix Combination Therapy in Women with Endometriosis
From GlobeNewswire News Releases
Myovant Sciences Announces New Employment Inducement Grants Under NYSE Rule 303A.08
From GlobeNewswire News Releases
Data & News supplied by www.cloudquote.io
Stock quotes supplied by Barchart
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.